-
公开(公告)号：US11016099B2
公开(公告)日：2021-05-25
申请号：US15759330
申请日：2016-09-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, Jr.
Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
-
公开(公告)号：US20220373539A1
公开(公告)日：2022-11-24
申请号：US17328816
申请日：2021-05-24
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, JR.
Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
-
Patent Agency Ranking
公开(公告)号：US20220144935A1
公开(公告)日：2022-05-12
申请号：US17536663
申请日：2021-11-29
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, JR.
IPC: C07K16/24 , G01N33/68 , A61K39/395
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
-
公开(公告)号：US11220541B2
公开(公告)日：2022-01-11
申请号：US16063803
申请日：2016-12-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, Jr.
IPC: C07K16/24 , G01N33/68 , A61K39/395 , A61K39/00
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
-
公开(公告)号：US20180252728A1
公开(公告)日：2018-09-06
申请号：US15759330
申请日：2016-09-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Grasser, JR.
CPC classification number: G01N33/6869 , A61K2039/505 , C07K16/244 , G01N2800/065 , G01N2800/52 , Y02A50/41
Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
-
公开(公告)号：US09914779B2
公开(公告)日：2018-03-13
申请号：US14360087
申请日：2012-11-21
Applicant: AMGEN INC.
Inventor： Dominique Christian Borie , Hailing Hsu , Wei-Jian Pan , William Rees , Barbara Anne Sullivan
IPC: A61K39/395 , C07K16/18 , C07K16/28 , G01N33/569 , A61K39/00
CPC classification number: C07K16/2842 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/2839 , C07K2317/90 , G01N33/56972 , G01N2333/70546 , G01N2800/065 , G01N2800/52
Abstract: There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition.
-
公开(公告)号：US20200262907A1
公开(公告)日：2020-08-20
申请号：US16063803
申请日：2016-12-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jinging Chen , Robert A. Gasser, JR.
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
-
-
-
-
-
-
Search Results
7
records
(took 0.017 seconds)
